Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions

Wolska-Washer, A; Robak, T

Robak, T (通讯作者)，Med Univ Lodz, Dept Hematol, Lodz, Poland.;Robak, T (通讯作者)，Copernicus Mem Hosp, Dept Gen Hematol, Lodz, Poland.

FRONTIERS IN ONCOLOGY, 2023; 13 ():

Abstract

Zanubrutinib (BGB-3111, Brukinsa((R)), BeiGene) is a next-generation irreversible inhibitor of Bruton's tyrosine kinase (BTK), developed by BeiGene in......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索